Show simple item record

dc.contributor.authorBoyd, Peter
dc.contributor.authorFetherston, Susan M.
dc.contributor.authorMcCoy, Clare F.
dc.contributor.authorMajor, Ian
dc.contributor.authorMurphy, Diarmaid J.
dc.contributor.authorKumar, Sandeep
dc.contributor.authorHolt, Jonathon
dc.contributor.authorBrimer, Andrew
dc.contributor.authorBlanda, Wendy
dc.contributor.authorDevlin, Brid
dc.contributor.authorMalcolm, R. Karl
dc.identifier.citationBoyd, P., Fetherston, S. M., McCoy, C.F., Major, I., Murphy, D.J., Kumar., S., Holt, J., Brimer, A., Blanda, W., Devlin, B., Malcolm, R. K. (2016). Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. International Journal of Pharmaceutics. 511(1): 619-629.
dc.identifier.otherArticles - Materials Research Instituteen_US
dc.description.abstractA matrix-type silicone elastomer vaginal ring providing 28-day continuous release of dapivirine (DPV) ⿿ a lead candidate human immunodeficiency virus type 1 (HIV-1) microbicide compound ⿿ has recently demonstrated moderate levels of protection in two Phase III clinical studies. Here, next-generation matrix and reservoir-type silicone elastomer vaginal rings are reported for the first time offering simultaneous and continuous in vitro release of DPV and the contraceptive progestin levonorgestrel (LNG) over a period of between 60 and 180 days. For matrix-type vaginal rings comprising initial drug loadings of 100, 150 or 200 mg DPV and 0, 16 or 32 mg LNG, Day 1 daily DPV release values were between 4132 and 6113 μg while Day 60 values ranged from 284 to 454 μg. Daily LNG release ranged from 129 to 684 μg on Day 1 and 2⿿91 μg on Day 60. Core-type rings comprising one or two drug-loaded cores provided extended duration of in vitro release out to 180 days, and maintained daily drug release rates within much narrower windows (either 75⿿131 μg/day or 37⿿66 μg/day for DPV, and either 96⿿150 μg/day or 37⿿57 μg/day for LNG, depending on core ring configuration and ignoring initial lag release effect for LNG) compared with matrix-type rings. The data support the continued development of these devices as multi-purpose prevention technologies (MPTs) for HIV prevention and long-acting contraception.en_US
dc.relation.ispartofInternational Journal of Pharmaceuticsen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland*
dc.subjectHIV microbicideen_US
dc.subjectHormonal contraceptionen_US
dc.subjectSilicone elastomer vaginal ringen_US
dc.subjectMultipurpose prevention technologyen_US
dc.subjectFormulation developmenten_US
dc.titleMatrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrelen_US
dc.title.alternativeDapivirine and levonorgestrel vaginal ringsen_US
dc.contributor.sponsorThe work was supported by a grant to Queen’s University Belfast from The International 473 Partnership for Microbicides, through generous support from the Ministry of Foreign Affairs of 474 the Netherlands and the American people through the United States Agency for International 475 Development (USAID) through the President’s Emergency Plan for AIDS Relief (PEPFAR).en_US
dc.rights.accessOpen Accessen_US
dc.subject.departmentMaterials Research Instituteen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland